| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rheumatology 2002; 41: 1367-1374
© 2002 British Society for Rheumatology
Original Papers |
The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD courses
Division of Rheumatology, Department of Internal Medicine III, University of Vienna and
1 Second Department of Medicine, Lainz Hospital, Vienna, Austria
Background. Therapy of rheumatoid arthritis (RA) is typically characterized by the sequential use of disease-modifying anti-rheumatic drugs (DMARDs). This study aimed to reveal treatment patterns with traditional DMARDs and their changes during the two decades before the recent introduction of new DMARDs.
Methods. A total of 593 RA patients were followed from their first presentation to our clinic throughout the course of their disease; 222 patients received their first DMARD therapy while under our care. More than 2300 patient years of therapy were analysed for the efficacy [using C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) as surrogates] and duration of drug therapy of consecutive DMARDs.
Results. Before 1985, 65–90% of initial DMARDs were gold compounds, but their use decreased continuously thereafter. Antimalarial (AM) drugs were important initial DMARDs in new patients at all times, whereas sulphasalazine (SSZ) and methotrexate (MTX) gained increasing significance after 1985 (the first DMARD was MTX in up to 29% of new patients). Penicillamine (DPA), azathioprine (AZP), cyclosporin (CyA) and combination therapies were not usually employed initially, but were reserved for the later course of the disease. Gender, age and rheumatoid factor were not different between patients receiving different DMARDs. The baseline acute-phase response was higher in patients treated with MTX (mean CRP 3.5 mg/dl) than in those treated with SSZ (CRP 2.4 mg/dl; P < 0.05) or AM (CRP 2.1 mg/dl; P < 0.05), suggesting that MTX was used preferentially in patients with high disease activity. On the other hand, once AM or SSZ had been discontinued, MTX was the most common subsequent DMARD (in 31 and 56% respectively). Comparison of first DMARDs with subsequent ones revealed that first DMARDs were more effective: the acute-phase response decreased most prominently during first therapies (CRP reduction was 1.28 mg/dl during first courses and 0.35 mg/dl during fourth or later courses; P < 0.01); and retention rates were significantly longer for first compared with subsequent therapies (median of 24.5 months for first and 18.6 months for fourth or subsequent therapies; P < 0.001).
Conclusion. MTX was the most commonly employed DMARD therapy for RA and was used increasingly as first therapy in newly diagnosed RA. Patients with high disease activity were given MTX therapy more often than other DMARDs, while those with low activity were more likely to receive SSZ or AM, and MTX on failure of these drugs. First DMARDs in new patients were retained longer than subsequent DMARDs, apparently because they are more effective.
KEY WORDS: Rheumatoid arthritis, First DMARD, Consecutive DMARD, Efficacy.
Correspondence to: J. S. Smolen, Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Vienna General Hospital, Waehringer Guertel 18–20, A-1090 Vienna, Austria.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S L Hider, A J Silman, W Thomson, M Lunt, D Bunn, and D P M Symmons Can clinical factors at presentation be used to predict outcome of treatment with methotrexate in patients with early inflammatory polyarthritis? Ann Rheum Dis, January 1, 2009; 68(1): 57 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Sokka and T. Pincus Ascendancy of weekly low-dose methotrexate in usual care of rheumatoid arthritis from 1980 to 2004 at two sites in Finland and the United States Rheumatology, October 1, 2008; 47(10): 1543 - 1547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M van der Kooij, J. K de Vries-Bouwstra, Y. P M Goekoop-Ruiterman, D. van Zeben, P. J S M Kerstens, A. H Gerards, J. H L M van Groenendael, J. M W Hazes, F. C Breedveld, C. F Allaart, et al. Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score Ann Rheum Dis, October 1, 2007; 66(10): 1356 - 1362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Schoels, T Kapral, T Stamm, J S Smolen, and D Aletaha Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study Ann Rheum Dis, August 1, 2007; 66(8): 1059 - 1065. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Andrianakos, P. Trontzas, F. Christoyannis, E. Kaskani, Z. Nikolia, E. Tavaniotou, A. Georgountzos, P. Krachtis, and for the ESORDIG study group Prevalence and management of rheumatoid arthritis in the general population of Greece--the ESORDIG study Rheumatology, December 1, 2006; 45(12): 1549 - 1554. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Hyrich, K. D. Watson, A. J. Silman, D. P. M. Symmons, and The BSR Biologics Register Predictors of response to anti-TNF-{alpha} therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register Rheumatology, December 1, 2006; 45(12): 1558 - 1565. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S L Hider, A Silman, D Bunn, S Manning, D Symmons, and M Lunt Comparing the long-term clinical outcome of treatment with methotrexate or sulfasalazine prescribed as the first disease-modifying antirheumatic drug in patients with inflammatory polyarthritis Ann Rheum Dis, November 1, 2006; 65(11): 1449 - 1455. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Sany, P Bourgeois, A Saraux, S Durieux, A Lafuma, J P Daures, F Guillemin, and J Sibilia Characteristics of patients with rheumatoid arthritis in France: a study of 1109 patients managed by hospital based rheumatologists Ann Rheum Dis, October 1, 2004; 63(10): 1235 - 1240. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. P. K. Nell, K. P. Machold, G. Eberl, T. A. Stamm, M. Uffmann, and J. S. Smolen Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis Rheumatology, July 1, 2004; 43(7): 906 - 914. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D Aletaha, T Stamm, T Kapral, G Eberl, J Grisar, K P Machold, and J S Smolen Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study Ann Rheum Dis, October 1, 2003; 62(10): 944 - 951. [Abstract] [Full Text]
|
|
|
|
|
|
D Aletaha, T Kapral, and J S Smolen Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis Ann Rheum Dis, May 1, 2003; 62(5): 482 - 486. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D Aletaha and J Smolen Authors' reply Ann Rheum Dis, May 1, 2003; 62(5): 494 - 495. [Full Text]
|
|